No description available.

eEF-2K, also known as CaM kinase-III, is an atypical protein kinase which negatively regulates the global rate of protein synthesis through the phosphorylation and inactivation of its substrate eEF-2. Recently eEF-2K has been validated as a novel target for anti-cancer therapy. However, a detailed understanding of the role of eEF-2K in cancer biology is unavailable. Mechanistic studies can often provide an understanding of enzyme function. Therefore, we determined the kinetic mechanism of eEF-2K using a peptide substrate (Acetyl-RKKYKFNEDTERRRFL-amide). We found that eEF-2K adopts a ternary-complex, steady state ordered mechanism, with ATP binding required before the peptide substrate. A good cellular inhibitor is required for elucidating the role of eEF-2K in cancer biology. To date, NH125 is the only inhibitor used to investigate the activity of eEF-2K in cells. Although it is reported as a specific inhibitor of eEF-2K, its exact mode of action has not been reported. Through in-vitro assays and cellular studies, we found that NH125 is a non-specific inhibitor of eEF-2K that blocks eEF-2 phosphorylation in cells. There is a great demand for specific inhibitors of eEF-2K. We developed a fluorescence high throughput assay system for eEF-2K. The assay utilizes the peptide substrate labeled with a Sox moiety whose phosphorylation can be monitored at 485 nm in the presence of magnesium. We also validated the assay in a screen of 30,000 compounds in 384 well plates. We found the assay to be robust and identified a relatively specific inhibitor of eEF-2K and determined its mechanism of action. We found it behaved as a slowly reversible inhibitor of eEF-2K with a two step inhibition mechanism - fast initial binding at the enzyme active site, followed by a slower inactivation step. We propose that the nitrile group on the compound binds to the active site thiol in the enzyme covalently forming a reversible thioimidate adduct to inactivate the enzyme. / text

No description available.

Embryonic stem (ES) cells can be maintained indefinitely in culture while retaining the ability to give rise to cellular derivatives from the three germ layers. These unique characteristics hold great promise for regenerative medicine and underscore the importance of understanding the molecular mechanisms behind ES cell maintenance. The embryonic stem cell state is supported by a delicate equilibrium of mechanisms that maintain pluripotency, prevent differentiation, and promote proliferation and survival. We sought to find genes that could contribute to one or more of these processes in human ES cells by using a gain-of-function screen of over 8000 human open reading frames (ORFs). We identify Vestigial-like 4 (Vgll4), a co-transcriptional regulator with no previously known function in ES cells, as a positive regulator for survival of human ES cells. Specifically, Vgll4 protects human ES cells from dissociation stress, and enhances colony formation from single cells. These effects may be attributable in part to the ability of Vgll4 to decrease the activity of initiator and effector caspases. Based on global transcriptional analysis, we hypothesize that Vgll4 enhances survival of hES cells at clonal densities by regulating changes in the cytoskeleton, which may in turn regulate pathways known to result in hES cell death. This dissertation introduces a novel approach for studying hES cell survival in the context of cell dissociation and presents Vgll4 as a novel regulator of this process. We also propose that Vgll4 could have multiple functions in hES cells including possible roles in pluripotency, cell cycle dynamics, Hippo pathway regulation, and \(TGF\beta\) signaling. A direct regulator of survival in human embryonic stem cells could have important implications for facilitating the generation of transgenic cell lines and reporters, thus harnessing the therapeutic application of these cells.

This report summarizes the process of writing, developing, directing and completing the short film In This Place. This film was produced as my graduate thesis film in the Department of Radio-Television-Film at the University of Texas at Austin in partial fulfillment of my Master of Fine Arts in Film Production degree. / text

Head mounted projection display (HMPD) technology, as an alternative to conventional head mounted displays (HMD), offers a potential of designing wide field-of-view (FOV), low distortion optical see-through HMDs (OST-HMDs). Existing HMPD designs, however, suffer from problems of low luminance and low image resolution, which limits the applications of such information displays for the scenarios which require high luminance and high image fidelity. The design of a polarized head mounted projection display (p-HMPD) was recently proposed to overcome the challenge of low luminous efficiency in existing HMPD designs. Polarization management was employed to reduce the light loss caused by beamsplitting in an HMPD.The work in this dissertation focuses on the development and evaluation of an SXGA resolution, high efficiency p-HMPD system. The main contributions are as follows. First, the key elements in the polarization management scheme of a p-HMPD were selected and their polarization performances were characterized by measuring their Mueller matrices, based on which the overall display performance of a p-HMPD was analyzed.Second, based on a pair of ferroelectric liquid-crystal-on-silicon (FLCoS) microdisplays, a compact illumination unit and a light-weight projection system were designed, from which a p-HMPD prototype was built. Following the prototype implementation, a series of calibrations were performed to obtain correct color presentation, desired focusing setting, and optical system characteristics necessary for achieving accurate registration between virtual objects and their counterparts in the real world.Third, the imaging properties of a retroreflective screen which is an essential part of a p-HMPD or HMPD were studied and its effects on the image resolution of an HMPD system were further characterized.Finally, the performance of the system was evaluated through two objective user experiments, including a visual acuity assessment and a depth perception accuracy assessment.

Loss of the promyelocytic leukemia (PML) protein is associated with genomic instability/cancer. There are several isoforms of the PML protein that localize in PML nuclear bodies (PML NBs). How each individual isoform contributes to the functions of PML NBs is unknown. The objective of this study was to identify and characterize PML isoform-I (PML-I) specific protein-protein interactions. Using yeast two-hybrid screens, several interacting partners of PML-I were identified that play roles in translational regulation, including eukaryotic initiation factor 3 subunit K (eIF3K). Our studies demonstrated that eIF3K interacts with PML-I in vitro and in vivo. Through its interaction with eIF3K, overexpression of PML-I resulted in the concomitant increase in eIF3K protein levels in mammalian cells. This suggests that PML-I may be involved in regulating eIF3K protein translation or stability, which in turn could affect translation of specific mRNAs or global translation in cancer cells with reduced expression of PML-I.

LACOME, the Large Collaborative Meeting Environment, is a collaboration system that allows multiple users to simultaneously publish their computer desktops (workspace) and/or windows on a large shared display via a network connection. Once published, windows or even full desktops can be moved, resized, and iconified; optionally, users can even interact with the content of other users. LACOME was originally designed and developed at The University of British Columbia; we extend the system to consider privacy and security concerns. We conducted a series of focus groups to obtain feedback on the initial design of the system. Based on our findings, we developed high level design requirements for future iterations of LACOME; these include the need for addressing privacy and security concerns when moving from the use of LACOME in a co-located setting to the overarching goal of its use in a mixed presence environment. We implemented new features that provide enhanced awareness of users’ shared workspaces and the interactions of others with them. We also developed an access control framework in the system that allows users to assign permissions on an ad-hoc basis. We undertook an initial evaluation of the LACOME system to evaluate the overall system and the changes that we made to it.

Biosolids are the nutrient-rich organic residual materials resulting from the treatment of domestic sewage at a wastewater treatment facility, and are increasingly land-applied for agricultural and land-reclamation purposes as part of the wastewater management process. While the presence and fate of estrogenic endocrine-disruptors (eEDCs) in wastewater has been extensively studied, much less focus has been given to examining the presence and fate of eEDCs during biosolids treatment. In particular, little work has been done to measure the net estrogenic potency of biosolids using in vitro bioassays, such as the Yeast Estrogen Screen (YES) assay. This is despite the fact that widespread land-application of biosolids provides for the direct introduction of eEDCs into terrestrial and aquatic environments. The relative scarcity of bioassay-based net estrogenicity data for sludges and biosolids is in large part due to the analytical challenges involved in working with such a complex sample matrix. Comprehensive sampling at wastewater treatment plants in Guelph and London, ON, demonstrated that the estrogenicity of anaerobically-treated biosolids is considerably lower (12.0-19.7 ng/g estradiol-equivalents) than that reported in earlier published studies. The results of the present study were made possible due to the development of a sample preparation methodology that overcame the toxic effects that sludge and biosolid samples typically exert on yeast cells in the YES assay. An anti-estrogenicity assay was also applied for the first time to sludges/biosolids to measure the extent to which antagonistic compounds ‘block’ the response of the YES assay. The results of these tests suggest that although the net estrogenicity of anaerobically treated solids is indeed low, up to twice the amount of estrogenicity measured by the YES assay may be masked in biosolids by the presence of antagonistic compounds. While aerobic treatment conditions reduced net estrogenicity to at-or-below detectable levels, net estrogenicity remained relatively constant throughout the unit processes of the anaerobic treatment train. Biosolid ageing during storage led to an overall decrease in net estrogenicity of both conventionally-treated “restricted use” and advanced-treated “unrestricted use” anaerobic biosolids. However, levels of net estrogenicity were observed to spike during the early stages of storage, particularly under freeze/thaw conditions. / Natural Science and Engineering Research Council of Canada (NSERC) PGS-D3 scholarship, Water Environment Association of Ontario, Canadian Water Network

<p>Background and objectives: Apoptosis is a process in which a cell programmes its own death. It is a highly organized physiological mechanism in which injured or damaged cells are destroyed. Apart from physiological stimuli however, exogenous factors can induce apoptosis. Many anti-cancer drugs work by activating apoptosis in cancer cells. Natural substances have been found to have the ability to induce apoptosis in various tumour cells and these substances have been used as templates for the construction of&nbsp / novel lead compounds in anticancer treatment. On the other hand, alkylating agents such as cisplatin, cis- [PtCl2 (NH3) 2] have been widely used as antineoplastic agents for a&nbsp / wide variety of cancers including testicular, ovarian, neck and head cancers, amongst others. However, the use of cisplatin as an anticancer agent is limited due to toxicity and resistance problems. The aim of this present study was to screen the leaves of Rhus laevigata, a South African indigenous plant, for the presence of pro-apoptotic and&nbsp / anti-proliferative natural compounds and also to screen newly synthesised palladium based complexes (15 and 57) and a platinum based complex (58) for their antineoplastic&nbsp / activities tested against a panel of cell lines. Results. The results showed that crude methanol extracts from Rhus laevigata as well as the newly synthesised palladium based complexes (15 and 57) and a platinum based complex (58) induced apoptosis in the cell lines tested, as demonstrated by the externalization of phosphatidylserine, mitochondrial membrane permeabilization,caspase-3 activation, and DNA fragmentation. Caski (cervical cancer) and H157 (non small cell lung carcinoma) cell lines treated with the methanol extract from Rhus laevigata however, were more resistant to apoptosis induction. Among the metallocomplexes, complexes 15 and 57, palladium based complexes, were the most active. Conclusion: The methanol extract from the leaves of Rhus laevigata contain pro-apoptotic and antiproliferative natural compound(s), which need to be characterised and elucidated as they could provide the much-needed lead compounds in the fight against cancer. On the other hand the newly synthesized palladium complexes also need further evaluation to&nbsp / see if they can be used as anticancer agents that can overcome the problems associated with cisplatin.</p>